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Key Points
• Flt3L is a biomarker of
progenitor cell mass
in AML.
•Measurement of Flt3L
during induction che-
motherapy and follow-
up provides prognostic
information.
Fms-like tyrosine kinase 3 (Flt3) is expressed on progenitor cells and acutemyeloid leukemia
(AML) blasts. Fms-like tyrosine kinase 3 ligand (Flt3L) is detectable during homeostasis and
increases in hypoplasia due to genetic defects or treatment with cytoreductive agents.
Conversely, Flt31 AML is associated with depletion of Flt3L to undetectable levels. After
induction chemotherapy, Flt3L is restored in patients entering complete remission (CR) but
remains depressed in those with refractory disease. Weekly sampling reveals marked
differences in the kinetics of Flt3L response during the ﬁrst 6 weeks of treatment,
proportionate to the clearance of blasts and cellularity of the bone marrow. In the UK NCRI
AML17 trial, Flt3L was measured at day 26 in a subgroup of 140 patients with Flt3 mutation
randomized to the tyrosine kinase inhibitor lestaurtinib or placebo. In these patients,
attainment of CR was associated with higher Flt3L at day 26 (Mann-Whitney U P , .0001).
Day 26 Flt3L was also associated with survival; Flt3L #291 pg/mL was associated with
inferior event-free survival (EFS), and Flt3L.1185 pg/mLwas associated with higher overall
survival (OS; P 5 .0119). The separation of EFS and OS curves increased when minimal
residual disease (MRD) status was combined with Flt3L measurement, and Flt3L retained
a near-signiﬁcant association with survival after adjusting for MRD in a proportional
hazards model. Serial measurement of Flt3L in patients who had received a hematopoietic
stem cell transplant for AML illustrates the potential value of monitoring Flt3L to identify
relapse. Measurement of Flt3L is a noninvasive test with the potential to inform clinical
decisions in patients with AML.
Introduction
Acute myeloid leukemia (AML) is a high-risk malignancy with fewer than one-third of patients surviving at
5 years.1,2 Despite intensive chemotherapy, therapeutic resistance and relapse are the main causes of
treatment failure. The early identification of primary treatment refractoriness is especially challenging
and independent of standard clinical, cytogenetic, and molecular risk factors,3 even with integrated
molecular genetic information.4 Large multicohort studies show that #30% of younger patients have
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primary refractory disease or relapse-free survival (RFS) #3
months, rising to 40% with RFS #6 months and 57% with RFS
#1 year.3 A limited ability to predict a poor therapeutic response, in
spite of advances in genetic risk profiling and minimal residual
disease (MRD) detection, continues to impede the delivery of risk-
adapted therapy.5-7 Salvage after relapse is also disappointing, with
,50% achieving a subsequent complete remission (CR), leading to
median survivals of,1 year.8 Outcomes are considerably worse for
patients .60 years, who constitute the majority of cases.9
Fms-like tyrosine kinase 3 (Flt3) ligand (Flt3L) is a growth factor
involved in the maintenance and proliferation of hematopoietic stem
and progenitor cells.10 Its receptor, Flt3 (CD135), is a tyrosine
kinase expressed predominantly on primitive CD341 CD38low
progenitor fractions.11 Several lines of evidence indicate that
Flt3L rises when the hematopoietic stem cell compartment is
compromised. Flt3L is increased in Fanconi anemia, acquired
aplastic anemia, chemotherapy- or radiotherapy-induced aplasia,
and heterozygous GATA2 mutation.12-17 Elevated Flt3L was also
observed in patients with AML at day 15 of treatment and shown
to be a potential mechanism of resistance to therapy with Flt3
inhibitors.10
Conversely, suppression of Flt3L in association with expansion of
hematopoietic progenitors has not been reported. Previous studies
investigating hypercellularity associated with myelodysplastic syn-
drome (MDS) lacked a sufficiently sensitive enzyme-linked immu-
nosorbent assay (ELISA) to determine levels much below the
normal range.18 Mobilization of peripheral blood stem cells with
granulocyte colony-stimulating factor is paradoxically associated
with a slight elevation of Flt3L.19,20 An inverse relationship between
Flt3L and cells bearing its receptor might be predicted from the
molecular control of other elements of hematopoiesis such as
platelets.21
Here, we show that the presence of CD1351 AML blasts is
associated with significant depression of Flt3L and that measurement
of this biomarker may have utility in diagnosis, early assessment of
response to therapy, and monitoring of remission status.
Methods
Single-center patients and controls
Patients with heterozygous mutation of GATA2, aplastic anemia,
MDS, and AML were recruited from the Northern Centre for Cancer
Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS
Foundation Trust under ethical permission from the Newcastle
and North Tyneside Research Ethics Committee 1 Reference 08/
H0906/72 (cohort A). Informed consent was obtained in accor-
dance with the Declaration of Helsinki. Additional patients with AML
were recruited from Johns Hopkins Sydney Kimmel Comprehensive
Cancer Center, Baltimore under the institutional review board–
approved protocol J10145. A total of 84 patients were recruited at
Newcastle, United Kingdom and 8 at Johns Hopkins, Baltimore,
MD (cohort B). All but 2 patients received intensive induction
chemotherapy with cytarabine in combination with daunorubicin,
etoposide, or mitoxantrone. Details of all patients included in the
study under these protocols are summarized in supplemental Table 1.
Healthy control blood was obtained from volunteer donors.
AML17 patients
The UK NCRI AML17 study (ISRCTN 55675535) was a large,
prospective phase 3 multicenter trial for patients with newly
diagnosed AML or high-risk MDS ($10% marrow blasts) that ran
2009-2014 at .130 centers in the United Kingdom, Denmark, and
New Zealand, recruiting 3583 patients.22,23 325 patients with Flt3
mutation were randomized 2:1 to receive lestaurtinib (CEP701);
140 of those randomized provided a blood sample at day 26 for
measurement of Flt3L. 5 patients were excluded from the analysis of
CR/no CR, because these data were missing. MRD determined by
reverse transcription quantitative polymerase chain reaction (RT-
qPCR) for mutated NPM1 was performed on 2 samples of bone
marrow (BM) only, 24 samples of paired BM and peripheral blood,
and 30 samples of peripheral blood only. The result was defined
as positive if, from any source, there was amplification in $2 of 3
replicates with cycle-threshold values of #40 in samples achieving
ABL1 control amplification within 30 cycles according to Europe
Against Cancer criteria.24 Flow cytometry MRD was performed
centrally on peripheral blood or BM using a standardized gating
strategy that screened for leukemia-associated immunopheno-
types with sensitivity of detection of 0.2% to 0.05%, as described
previously.25
Flt3L ELISA
Serum Flt3L was measured with quantikine human Flt3/Flk-2 ligand
immunoassay according the manufacturer’s instructions (R&D
Systems).
Flow cytometry
BM or peripheral blood blasts were prepared with ficoll gradients
and stained in aliquots of;1 million cells. Antibodies were from BD
Biosciences (www.bdbiosciences.com) unless stated otherwise and
are denoted as: antigen fluorochrome (clone), CD3 fluorescein
isothiocyanate (FITC) (SK7), CD10 phycoerythrin (PE)–Texas red
(B-Ly6; Beckman Coulter; www.beckmancoulter.com), CD14 FITC
(M5E2), CD16 FITC (NKP15/Leu-11a), CD19 FITC (4G7), CD20
FITC (L27), CD34 APCCy7 (581), CD38 PECy7 (HB7), CD45
V450 (2D1), CD45RA BV510 (HI100; BioLegend), CD56 FITC
(NCAM16.2), CD90 PerCPCY5.5 (5E10; BioLegend), CD123
PerCPCY5.5 (7G3), and CD135 PE (4G8), HLA-DR V500 (L243/
G46-6). Events were acquired with a BD Biosciences Fortessa X20
running Diva version 8 and analyzed with Tree Star FlowJo version
7.6.5. Blasts were identified as a high forward scatter/side scatter
lineage-negative population and median fluorescence intensity (MFI)
of CD135 was calculated by subtraction of an appropriate isotype
control.
Statistical analyses
Figures were plotted in R (version 3.0.1; http://www.r-project.org/)
or Prism (version 7.0d; GraphPad Software). All statistical analyses
for AML17 patient data were carried out in R 3.0.1. Date of death
was used to calculate overall survival (OS). Event-free survival (EFS)
events were defined as failure to achieve CR, disease relapse, or
death from any cause. For both survival end points, patients without
a date of relapse or death were censored at the date of last visit or
the date at which patients were last known to be alive. Remission
status was measured using 7 categories, namely CR, death
before chemotherapy started, induction death, resistant disease,
Partial remission, CR with incomplete count recovery, and other.
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Remission status was then dichotomized into CR vs non-CR. The
optimal cut point separating patients in CR from those with no
CR was defined by the Youden method using the receiver operating
characteristic (ROC) analysis in the R package Optimal Cutpoints.26
We then plotted a ROC curve for this cut point and determined
the area under the curve (AUC), sensitivity, and specificity. The R
package Survminer was then used to determine the optimal cut point
for OS and EFS based on the maximally selected log-rank statistic.
The 2 survival curves split by this cut point were then plotted using
the descriptive Kaplan-Meier method with the log-rank P value.
Results
Association of Flt3L with progenitor cell mass and
Flt3 expression in AML
The relationship between Flt3L level and progenitor cell mass was
explored in a number of distinct patient groups recruited at the
Newcastle center, including cohort A patients with AML (Figure 1A).
As reported previously, patients with hypoplasia of the hematopoietic
stem/progenitor compartment due to aplastic anemia or germline
GATA2 mutation have very elevated serum Flt3L.12,13,16,17 A cohort
of ambulatory patients with MDS showed increased variance of Flt3L
levels, while patients admitted for treatment of AML mostly had low
or undetectable levels of Flt3L. A potential link between decreasing
Flt3L and progression to AML was suggested by the observation
that although patients with excess blasts had a range of Flt3L levels
(Figure 1A, asterisks), the 3 MDS patients with the lowest Flt3L
(#21 pg/mL) progressed to AMLwithin 6 months. Of 75 consecutive
patients admitted for treatment of AML, 71 had Flt3L below the level
of healthy controls (range, 48.3-173.8 pg/mL; n 5 20) and 63 had
Flt3L below the limit of detection of 7 pg/mL. Further clinical details of
patients with AML are given in supplemental Table 1.
Clinical variables were explored in order to try to understand the
reason for Flt3L suppression in most, but not all, cases of AML.
Although there was a clear inverse relationship between percent-
age of BM blasts and Flt3L across all disease groups, there were no
statistically significant relationships within the AML cohort between
white blood cell count at diagnosis, blast percentage in BM,
cytogenetics, presence of Flt3 internal tandem duplication (ITD),
blast phenotype, and disease stage (supplemental Figure 1). The
only notable feature was an association between the diagnosis of
acute promyelocytic leukemia (APL) or the presence of t(15;17)
in patients with normal Flt3L. There were 5 cases of APL, of
which 3 had normal Flt3L, compared with only 1 of 70 cases of
non-APL.
The expression of Flt3 (CD135) on AML blasts was analyzed
by flow cytometry in a subset of patients shown in Figure 1A,
including the 5 patients with APL. This confirmed that Flt3
was expressed at a lower level on APL than most AML blasts
(Figure 1B) and that there was an approximate inverse relationship
between the expression of Flt3 and the level of Flt3L across all
cases (Figure 1C).
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Figure 1. Association of Flt3L with progenitor cell mass and Flt3
expression in AML cohort A. (A) Serum Flt3L measured by ELISA in
healthy controls (range, 48.3-173.8 pg/mL; shaded region), individuals
with heterozygous germline GATA2 mutation, acquired aplastic anemia
(AA), MDS, APL (open symbols), and AML. Asterisks in the MDS cohort
indicate patients with excess blasts. Where Flt3L was reported as
undetectable, data were set to the limit of detection at 7 pg/mL.
Numbers in each cohort are shown in parentheses. (B) Level of Flt3
(CD135) expression indicated by MFI (minus isotype control) in control
CD341 BM progenitors, APL blasts, and AML blasts. The numbers in
each cohort are indicated in parentheses. Note MFI is a log scale. (C)
Inverse relationship between CD135 expression and Flt3L in 14 AML
and 4 APL patients in whom both measurements were performed.
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Association of Flt3L with remission
assessment postchemotherapy
Further samples, following 2 rounds of intensive chemotherapy,
were available from 28 patients in cohort A (Newcastle) who had
undetectable Flt3L at diagnosis. These were taken at the time of
remission assessment, between 28 and 42 days after the start of
each round of chemotherapy. Fifteen patients were in morpholog-
ical CR after both courses of chemotherapy and showed recovery of
Flt3L to normal or supranormal levels at both time points (Figure 2A).
A further 8 patients did not achieve morphological CR after the first
course but subsequently entered remission after the second
course (daunorubicin and cytarabine or fludarabine, cytarabine,
and idarubicin salvage) (Figure 2B). In contrast, Flt3L remained
suppressed in 5 patients who did not enter CR after 2 cycles of
chemotherapy. In addition, 3 patients thought to be in morpholog-
ical CR after the first course failed to show any appreciable
recovery of Flt3L after either course 1 or course 2. These patients
all relapsed within 6 months of diagnosis at 114 to 172 days
compared with RFS of 317 to 825 days for patients in A and B,
whose Flt3L was elevated after treatment (Figure 2C).
Kinetics of Flt3L response during
induction chemotherapy
The preceding data suggest that the level of Flt3L was highly
discriminatory between a state of normal hematopoiesis and the
presence of CD1351 AML blasts. Undetectable Flt3L appeared to
associate with resistant or refractory disease when measured
between courses of chemotherapy at the time of remission assess-
ments by BM aspiration. Weekly sampling was then performed in
a subset of 12 non-APL AML patients (4 in cohort A and 8 in cohort B)
in order to determine whether it might be possible to predict remission
status from the kinetics of Flt3L response. Six patients who eventually
achieved CR showed Flt3L elevation of 1000 to 4000 pg/mL, peaking
between days 14 and 21 and returning to the normal range after
chemotherapy (Figure 3A). In contrast, 4 patients who did not enter
CR showed more modest elevations of ,1000 pg/mL that sub-
sequently dropped back to below normal or undetectable levels at day
42 (Figure 3B). Two patients in the series remained pancytopenic
after chemotherapy induction and were found to be have hypocellular
BMs without detectable blasts. In these cases, Flt3L remained high
(.1000 pg/mL) (Figure 3C). One was salvaged by hematopoietic
stem cell transplantation, but the other died of sepsis without any
count recovery.
Analysis of AML17 CR and survival according to
course 1 Flt3L
Weekly sampling in 12 patients suggested that the response of
Flt3L to chemotherapy might predict attainment of CR. In order to
test this in a larger cohort, we reanalyzed Flt3L levels at day 26 of
induction recorded in 140 patients with Flt3 ITD or kinase domain
mutation who were treated within the UK NCRI AML17 trial. In these
patients, a single Flt3L measurement was performed at day 26 of
induction, following 10 days of chemotherapy and 14 days of either
tyrosine kinase inhibitor lestaurtinib or placebo.23 A CR status post
course 1 was reported in 135 of 140 patients. We first analyzed
Flt3L in relation to attainment of CR and found a significantly lower
median level in patients not achieving CR, including 4 patients with
undetectable levels (Figure 4A). A ROC curve identified an optimal
cut point of 116 pg/mL with AUC of 0.735, sensitivity of 0.721, and
specificity of 0.737. There was no difference in Flt3L according to
randomization to lestaurtinib or NPM1 mutation status (not shown).
This analysis suggested that Flt3L measured at a single point on
day 26 had a modest ability to predict CR status after course 1.
Consistent with the previous data from cohort A (Figure 2), 4 out of
5 patients with undetectable Flt3L at day 26 were reported as failing
to achieve CR. In practice, these patients may be salvaged by the
second course of chemotherapy, as also illustrated in Figure 2, so
there is not necessarily an association between Flt3L measured
during the first course and more distal outcomes such as EFS and
OS. In order to test this, a maximally selected log-rank test was used
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Figure 2. Serial serum Flt3L measurements in AML patients. (A) Patients were sampled at diagnosis and following each of 2 cycles of intensive chemotherapy with
daunorubicin and cytarabine (3110) or fludarabine, cytarabine, and idarubicin (cohort A, Newcastle; shaded regions indicate normal range). Patients who entered continuing
morphological CR after 2 courses maintained increasing Flt3L at remission assessments performed 28 to 42 days after the start of chemotherapy (range of detection, 7-1000
pg/mL; n 5 15; broken lines). (B) Patients who did not achieve morphological CR after the first course of chemotherapy but subsequently entered remission after the second
also demonstrated increasing Flt3L over both cycles (n 5 5; filled circles and solid lines). (C) Patients who remained refractory after 2 courses of chemotherapy had
undetectable Flt3L (n 5 5; open circles and solid lines). The graph also includes a further 3 patients thought to be in morphological CR after the first course of chemotherapy
who experienced relapse within 6 months.
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to define cut points for Flt3L in relation to EFS and OS. This
determined a significantly greater EFS for patients with Flt3L .291
pg/mL at day 26 (log rank P 5 .010; Figure 4B) and an OS
advantage for patients with Flt3L.1185 pg/mL (log rank P5 .0119;
Figure 4C). Of 140 patients with an Flt3L measurement, an
MRD assessment after course 1 was performed by flow cytometry
in 74 by NPM1 RT-qPCR in 56 patients and by both methods
in 28 patients. Combining these results, an MRD test by $1
methodology was available for 101 patients. Of the 28 patients with
both tests, positivity in either test result was scored as positive (see
supplemental Table 2 for details). As expected, patients with MRD
positive status by either test had a significantly lower chance of EFS
and OS (Table 1). We then probed the association between Flt3L
and survival, adjusting for MRD status as a covariable in Cox propor-
tional hazard regression models, using the optimal cut points previously
determined for EFS and OS to define Flt3L as a categorical variable.
Independently of MRD status, the level of Flt3L retained associations
with survival that were only just outside 95% confidence intervals
(Table 1). The additive effect of MRD and Flt3L was evident from the
separation of Kaplan-Meier curves, which showed greater divergence
and lower P values than groups defined by either variable alone
(Figure 4D-E).
Posttransplant remission assessment using Flt3L
In order to assess the potential utility of Flt3L in identifying patients
at risk of relapse following hematopoietic stem cell transplantation,
samples were collated from a calendar-driven prospective serum
collection from day27 to 24 months from patients receiving hema-
topoietic stem cell transplantation in cohort A. From this were
identified 8 sequential patients who relapsed and 7 patients in
continuing CR over the same period (Figure 5). In all patients, Flt3L
increased to a peak of ;1000 pg/mL during the aplastic phase,
immediately following conditioning. Flt3L remained at or above phys-
iological levels in 7 patients with sustained remission (Figure 5A)
but declined and became undetectable in 8 patients who
relapsed (Figure 5B). Samples were only collected every 3
months, so it was not always possible to observe a decline in
Flt3L prior to relapse. However, in 6 out of 17 posttransplant
relapses, a drop in Flt3L occurred $10 days prior to the diag-
nosis of relapse.
Discussion
Flt3L is a critical hematopoietic growth factor that becomes mark-
edly elevated in response to depletion of the hematopoietic stem/
progenitor compartment. Here, we show that it is depleted in the
overwhelming majority of patients with AML, the exceptions being
associated with low expression of the receptor Flt3 (CD135) by
blasts, as frequently observed in APL. These results are consistent
with a model in which the level of Flt3L is inversely related to the
abundance of Flt31 stem/progenitor cells or AML blasts. Several
previous reports have highlighted the expression of Flt3 in AML27,28
and documented that Flt3L may function as an autocrine growth
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Figure 3. Kinetics of Flt3L response during induction. Sequential patients with
weekly measurement of Flt3L during induction chemotherapy (n 5 12; 4 in cohort A
and 8 in cohort B). Dotted line indicates the timing of a single Flt3L measurement in
Figure 3. (continued) patients treated on the AML17 trial. (A) Weekly Flt3L in 6
patients entering CR following induction chemotherapy (B) Weekly Flt3L in 4
patients with refractory disease or partial response following induction chemother-
apy. (C) Weekly Flt3L in 2 patients rendered aplastic by induction chemotherapy
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factor29 and possibly attenuate the effect of Flt3 inhibitors during
therapy.10
Regulation of Flt3L production is not completely understood. In the
steady state, the major source appears to be nonhematopoietic30
but it is also secreted by activated and peripheral blood T cells.17,30
Alternative splicing produces membrane-bound Flt3L that may play
a major role in homeostasis but was not studied here.31 Preformed
Flt3L has also been described in progenitor cells and AML blasts.32
In mice, Flt3L has been described mainly in the hematopoiesis of
dendritic cells,33 but in humans, Flt3 is expressed by CD38low
CD45RA1 early progenitor cells, suggesting a more fundamental
role in the regulation of lymphomyeloid hematopoiesis.11,34
The potential utility of Flt3L to assist in the assessment of remission
between courses of chemotherapy was demonstrated by restora-
tion of Flt3L as patients entering remission, but not in the setting of
refractory disease. However, morphological assessment and Flt3L
were not always concordant. Five patients thought not to be in CR
after course 1 showed elevations of Flt3L that heralded attainment
of morphological CR after course 2. In 3 cases, CR was reported
but there was no restoration of Flt3L, and early relapse ensued. In
the larger cohort of patients taken from the AML17 trial, there was
a significantly different distribution of Flt3L in relation to CR status,
but a number of patients with low or undetectable Flt3L were
reported to be in CR. It is possible that some patients entering CR
overshoot the normal range, becoming transiently depressed. An
attractive alternative is that measurement of Flt3L will increase the
accuracy of assigning CR by morphology alone. Further prospective
study will be required to answer this question.
An MRD assessment after course 1 was performed by flow
cytometry or NPM1 RT-qPCR in 101 patients on AML17. A caveat
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Figure 4. Association between Flt3L and post–course 1
remission and survival. Serum Flt3L was measured on day
26 of induction in non-APL AML patients with Flt3 mutation
randomized to lestaurtinib (days 11-24) on the UK NCRI
AML17 trial. (A) Serum Flt3L at day 26 in patients who sub-
sequently achieved or did not achieve CR. Dotted line indi-
cates optimal cut point identified by the ROC curve: 116 pg/mL
(Mann-Whitney U P value). (B) EFS of subgroups with se-
rum Flt3L level $291 pg/mL (blue line) or ,291 pg/mL (red
line). Events include failure to achieve CR and relapse or
death from any cause. Threshold of Flt3L for maximum dis-
crimination identified by log-rank testing (log-rank P value). (C)
OS of subgroups with a serum Flt3L level $1185 pg/mL (blue
line) or ,1185 pg/mL (red line). Threshold of Flt3L for maxi-
mum discrimination identified by log-rank testing (log-rank P
value). (D) EFS of subgroups divided according to Flt3L level
$291 pg/mL and MRD negative (green line, n 5 17), $291
pg/mL and MRD positive (blue line, n 5 15), Flt3L ,291 pg/mL
and MRD negative (black line, n 5 23), or ,291 pg/mL
and MRD positive (red line, n 5 46) (log-rank P value). (E) OS
of subgroups divided according to Flt3L level $1185 pg/mL
and MRD negative (green line, n 5 10), $1185 pg/mL
and MRD positive (blue line, n 5 5), Flt3L ,1185 pg/mL and
MRD negative (black line, n 5 30), or ,1185 pg/mL and
MRD positive (red line, n 5 56) (log-rank P value).
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of our analysis is that these measurements may not be directly
comparable but were combined in the interest of greater statistical
power. Remarkably, a single measurement of Flt3L provided similar
hazard ratios for EFS and OS as these tests. Furthermore, the
combination of MRD status and Flt3L defined subgroups with highly
divergent EFS and OS, including 10 out of 101 elite survivors with
high Flt3L and undetectable MRD who had 100% survival. The
association between Flt3L and survival remained almost significant
(P # .06) after adjustment for MRD status in a Cox proportional
hazard model, suggesting that Flt3L reports independent prognos-
tic information.
Weekly Flt3L measurement provided a fascinating insight into the
dynamics of response to cytoreductive chemotherapy. Patients
achieving CR had significantly elevated Flt3L peaking just after
the end of therapy and returning to the normal range upon count
recovery. Those with refractory disease showed transient eleva-
tion of Flt3L followed by rapid depletion. Two patients who were
rendered aplastic maintained high levels in the absence of further
chemotherapy. Based on these observations, serum ELISA for Flt3L
appears to be a low-cost noninvasive method for the serial moni-
toring of patients during remission induction. In particular, Flt3L is
likely to dichotomize patients with delayed count recovery into those
with low Flt3L due to residual disease and those with high Flt3L and
hypoplasia. Tracking of the Flt3L response may thus potentially
reduce the need for serial invasive BM assessments and stratify
patients for further therapy.
The development of Flt3L as a prognostic tool is more challenging.
We took advantage of AML17 trial data in which a single measure-
ment was performed at day 26. A strong association with attainment
of CR was observed in the expected direction, at a cut point of
Table 1. Hazard ratios for survival in 101 patients from AML17 with
dual Flt3L measurement and MRD assessment after course 1
HR 95% CI Test P
EFS
Flt3L ,291 vs $291 0.51 0.31-0.84 Log rank .0076
MRD positive vs negative 0.38 0.23-0.61 Log rank .0001
Flt3L ,291 vs $291, adjusting for MRD 0.57 0.32-1.03 Cox .0600
OS
Flt3L ,1185 vs $1185 0.38 0.18-0.79 Log rank .0097
MRD positive vs negative 0.41 0.23-0.73 Log rank .0025
Flt3L ,1185 vs $1185, adjusting for MRD 0.25 0.06-1.05 Cox .0590
HR, hazard ratio; CI, confidence interval.
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Figure 5. Serial measurement of Flt3L after hematopoi-
etic stem cell transplantation. (A) Serial serum Flt3L
measurements in patients with non-APL AML undergoing he-
matopoietic stem cell transplantation remaining in continuous
remission (n 5 8; open circles and broken lines; shaded re-
gion indicates normal range). Patients were sampled prior to
conditioning (day 27), on the day of transplant (day 0), and
on days and months posttransplant, as indicated. Patients
were selected over the same period as panel B. (B) Serial se-
rum Flt3L measurements in 7 patients with non-APL AML un-
dergoing hematopoietic stem cell transplantation who
relapsed (n 5 7; filled circles and broken lines). Consecutive
relapsed patients #2 years posttransplant are reported. (C)
Interval between drop in Flt3L below the normal range and di-
agnosis of relapse. Summary of calendar-driven Flt3L mea-
surement in 17 patients indicating timing of the point at which
Flt3L first went below normal relative to the hematological di-
agnosis of relapse. Includes all patients in B with 10 additional
patients in whom $1 Flt3L measurement was recording
posttransplantation.
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116 pg/mL. This is approximately the median of the normal range,
reinforcing the rationale of Flt3L as a biomarker of progenitor
cell mass. A more accurate predictive tool might be developed from
serial weekly measurements in which the rate of rise, peak level, or
AUC could have higher discriminatory potential. Concerning longer-
term survival outcomes, we found discriminatory thresholds for EFS
and OS. EFS was inferior in patients with Flt3L ,291 pg/mL.
Failure to achieve CR was included as an event, so this subgroup
includes all patients with refractory disease who did not survive. A
subgroup of 20 patients with high Flt3L (.1185 pg/mL) also
enjoyed unusually good OS of .80% at 3 years compared with
;50% in the remainder of the cohort. The reason for this is not
immediately apparent. We speculate that very high levels of Flt3L
occur in association with deep remissions in chemosensitive dis-
ease, but further studies will be required to validate these thresholds
and determine their prognostic utility in the context of MRD assess-
ment. We note that all patients were taken from a relatively homo-
geneous genetic group with either Flt3 ITD or kinase domain
mutation. Consequently, we found no evidence to suggest that the
elite survivor subgroup group had unusually favorable genetics.
We explored the use of Flt3L measurement to detect relapse in
patients after hematopoietic stem cell transplantation. As expected,
there was elevation of Flt3L during aplasia and a recovery to normal
or supranormal in patients in continuing CR. Using a schedule of
sampling every 3 months, it was possible to detect relapse early in a
proportion of patients. As with postchemotherapy evaluation, Flt3L
may provide useful insights into pancytopenia in the posttransplant
patient, distinguishing between poor graft function or myelosup-
pression and incipient relapse. The temporal resolution of this would
clearly be improved by weekly sampling in future studies. Monitoring
for progression or relapse is not limited to transplant patients; 2
patients with MDS in whom Flt3L became undetectable as they
progressed to AML illustrate that Flt3L could facilitate the timing of
surveillance BM testing in this patient group.
Remission assessment after the first course of induction chemo-
therapy is a key milestone in achieving long-term RFS of AML.
Presently, the standard of care is expectant, and remission is
formally assessed by examination of the BM following hematopoi-
etic recovery. Patients will not know that they have resistant or
refractory disease until several weeks after completing the first
course of chemotherapy, a problem that is frequently compounded
by delayed blood count recovery in those most at risk of treatment
failure.
Treatment refractoriness is difficult to predict from clinical, cytoge-
netic, and molecular genetic information.3,4 An interim BM assess-
ment at day 15 may discern blast clearance and is routine practice
in many North American centers.35 However, this is often a nadir for
the patient in terms of cytopenia and attendant systemic illness, and
interpretation can be difficult. It is not a universal practice in Europe.7
The data presented here suggest that Flt3L may provide an
inexpensive, rapid, and noninvasive means of assessing remission
status in AML. As with MRD techniques, it is likely that performance
of the test will be specific to the intensity of treatment. For example,
a different kinetics of response has previously been reported in the
context of lower-intensity treatment with azacitidine and sorafenib.36
Finally, the response of Flt3L to chemotherapy is likely to reflect
multiple known risk factors in AML, including genetic subgroup,
blast count, and attainment of MRD-negative status. Large
prospective studies will be required to evaluate this information
in a stratified manner in order to determine whether Flt3L responses
are integrative of known risk factors or provide independent
prognostic information. Both have the potential to find utility in
clinical practice.
Acknowledgments
The authors thank Hyun Yu (Newcastle University) for assistance
with sample collection, Robert Hills (Oxford University) for pre-
liminary statistical analysis, and Paresh Vyas (Oxford University)
for helpful discussion.
C.W.-B. andS.K. are supported byCancer ResearchUK (CRUK)
Cardiff Experimental Cancer Medicine Centre core funding and
CRUK Clinical Research Committee Clinical Trials Unit Programme
Award core funding. P.M. and M.C. are supported by CRUK
(C30484/A21025), Histiocytosis UK, the Histiocytosis Associa-
tion, and Bright Red. The authors also acknowledge support from
NIHRNewcastle Biomedical Research Centre at Newcastle upon
Tyne Hospitals NHS Foundation Trust.
Authorship
Contribution: P.M. designed the study, acquired, analyzed, and
interpreted data, and drafted the manuscript; C.W.-B. analyzed and
interpreted data and performed critical revision; M.R.G., S.D.F., K.G.
A.P., S.P., H.M., R.D., A.G., and G.L.J. acquired and analyzed data;
V.B. acquired, analyzed, and interpreted data; A.M.D. and A.K.B.
acquired data; N.H.R. interpreted data and performed critical re-
vision of themanuscript; M.L. conceived and designed the study and
interpreted data; S.K. conceived and designed the study, interpreted
data, and performed critical revision; and M.C. conceived and
designed the study, analyzed and interpreted data, drafted the
manuscript, and performed critical revision.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
ORCID profiles: P.M., 0000-0002-8278-0463; V.B., 0000-
0002-3017-2474; R.D., 0000-0001-9333-5296; S.D.F., 0000-
0003-1869-180X; M.L., 0000-0003-0473-6982; M.C., 0000-
0001-6585-9586.
Correspondence: Matthew Collin, Institute of Cellular Medicine,
Newcastle University, Framlington Pl, Newcastle upon Tyne NE2
4HH, United Kingdom; e-mail: matthew.collin@ncl.ac.uk.
References
1. CRUK. Cancer statistics for the UK. Available at: www.cancerresearchuk.org/health-professional/cancer-statistics. Accessed 1 December 2018.
2. SEER. statfacts. Available at: https://seercancergov/statfacts/html/amyl.html. Accessed 1 December 2018.
22 OCTOBER 2019 x VOLUME 3, NUMBER 20 Flt3L IS A BIOMARKER IN AML 3059
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/20/3052/1502783/advancesadv2019000197.pdf by C
AR
D
IFF U
N
IVER
SITY user on 13 N
ovem
ber 2019
3. Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD
Anderson Cancer Center. Leukemia. 2015;29(2):312-320.
4. Walter RB, Othus M, Paietta EM, et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
[letter]. Leukemia. 2015;29(10):2104-2107.
5. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41.
6. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53-61.
7. Do¨hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood. 2017;129(4):424-447.
8. Thomas X, Raffoux E, Renneville A, et al. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the
ALFA-9802 trial. Leuk Res. 2012;36(9):1112-1118.
9. Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukemia in first relapse. Am J Hematol. 2013;88(9):758-764.
10. Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286-3293.
11. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;
19(1):138-152.
12. Lyman SD, Seaberg M, Hanna R, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia
and acquired aplastic anemia. Blood. 1995;86(11):4091-4096.
13. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic
anemia and chemotherapy-induced bone marrow aplasia. Blood. 1996;88(12):4493-4499.
14. Molyneux G, Gibson FM, Whayman M, Turton JA. Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female
CD-1 mouse. Int J Exp Pathol. 2008;89(2):159-170.
15. Bertho JM, Demarquay C, Frick J, et al. Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol. 2001;
77(6):703-712.
16. Bigley V, Haniffa M, Doulatov S, et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med. 2011;208(2):227-234.
17. Dickinson RE, Milne P, Jardine L, et al. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014;123(6):863-874.
18. Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD. Endogenous FLT-3 ligand serum levels are associated with
disease stage in patients with myelodysplastic syndromes. Leukemia. 1999;13(4):553-557.
19. Bojko P, Pawloski D, StellbergW, Schro¨der JK, Seeber S. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with
chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Ann Hematol. 2002;81(9):522-528.
20. Haidar JH, Bazarbachi A, Mahfouz R, Haidar HA, Jaafar H, Daher R. Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell
mobilization. J Hematother Stem Cell Res. 2002;11(3):533-538.
21. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339-3347.
22. Burnett AK, Russell NH, Hills RK, et al; UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML
induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878-3885.
23. Knapper S, Russell N, Gilkes A, et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated
AML. Blood. 2017;129(9):1143-1154.
24. Ivey A, Hills RK, Simpson MA, et al; UK National Cancer Research Institute AMLWorking Group. Assessment of minimal residual disease in standard-risk
AML. N Engl J Med. 2016;374(5):422-433.
25. Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies
outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36(15):1486-1497.
26. Lopez-Raton M, Rodriguez-Alvarez MX, Cadarso-Suarez C, Gude-Sampedro F. OptimalCutpoints: An R package for selecting optimal cutpoints in
diagnostic tests. J Stat Softw. 2014;61(8):1-36.
27. Meierhoff G, Dehmel U, Gruss HJ, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 1995;9(8):
1368-1372.
28. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996;10(4):588-599.
29. Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103(1):267-274.
30. Saito Y, Boddupalli CS, Borsotti C, Manz MG. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady
state and during immune responses. Eur J Immunol. 2013;43(6):1651-1658.
31. McClanahan T, Culpepper J, Campbell D, et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood. 1996;88(9):
3371-3382.
32. Chklovskaia E, JansenW, Nissen C, et al. Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface
of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood. 1999;93(8):2595-2604.
33. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt31 lymphoid and myeloid-committed
progenitors to Flt31 dendritic cells in vivo. J Exp Med. 2003;198(2):305-313.
3060 MILNE et al 22 OCTOBER 2019 x VOLUME 3, NUMBER 20
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/20/3052/1502783/advancesadv2019000197.pdf by C
AR
D
IFF U
N
IVER
SITY user on 13 N
ovem
ber 2019
34. Karamitros D, Stoilova B, Aboukhalil Z, et al. Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. Nat Immunol. 2018;
19(1):85-97.
35. Ofran Y, Leiba R, Ganzel C, et al. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “317” induction regimen for
acute myeloid leukemia. Am J Hematol. 2015;90(12):1159-1164.
36. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem
duplication mutation. Blood. 2013;121(23):4655-4662.
22 OCTOBER 2019 x VOLUME 3, NUMBER 20 Flt3L IS A BIOMARKER IN AML 3061
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/20/3052/1502783/advancesadv2019000197.pdf by C
AR
D
IFF U
N
IVER
SITY user on 13 N
ovem
ber 2019
